STRASS试验3年随访:类风湿关节炎TNF阻滞剂减量可持续性
该研究对STRASS随机对照试验完成者进行3年观察性延伸随访,评估类风湿关节炎稳定缓解患者TNF阻滞剂减量的可持续性。结果显示41%患者可实现持续减量或停药,但平均剂量仍为全剂量的66%,提示长期维持缓解仍需优化策略。
要点
- 41%患者3年内可实现持续TNF阻滞剂减量或停药。
- 平均TNF阻滞剂剂量为全剂量的66%,减量幅度有限。
- 20.8%患者切换至其他bDMARD,两组间无显著差异。
核心结论
- 在类风湿关节炎稳定缓解患者中,3年内41%可实现持续TNF阻滞剂减量或停药,但剂量减少幅度有限。
研究设计与样本
- STRASS随机对照试验的观察性3年延伸随访,回顾性收集完成者试验结束后1、2、3年临床数据,比较渐进减量组与维持组。
主要发现
- 96例患者(占完成者76.8%)有3年数据,11.5%停用TNF阻滞剂(维持组5.8% vs 减量组18.2%,p=0.06)。
- 30.2%维持减量方案(维持组28.8% vs 减量组31.8%,p=0.76),37.5%维持全剂量(维持组44.2% vs 减量组29.5%,p=0.14)。
- 平均TNF阻滞剂剂量为全剂量的66%(维持组74% vs 减量组58%,p=0.06),20.8%切换至其他bDMARD(维持组21.2% vs 减量组20.5%,p=0.94)。
关键数值与推荐
- 持续减量或停药定义为3年内无bDMARD治疗、持续间隔注射TNF阻滞剂或维持全剂量方案。
临床怎么用
- 对稳定缓解的类风湿关节炎患者可考虑TNF阻滞剂减量,但需监测维持缓解情况,减量后剂量仍可能接近全剂量的2/3。
局限性
- 为观察性延伸随访,仅纳入完成试验的患者,样本量有限,部分比较未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We have limited data on the sustainability of tumour necrosis factor (TNF)-blocker tapering in rheumatoid arthritis (RA) in remission over the long term in real-life settings. This study aimed to assess the probability of sustained dose reduction of TNF-blockers in an observational 3-year extended follow-up of the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS), a randomised controlled trial comparing progressive TNF-blocker injections (spacing arm (S-arm) to maintenance arm (M-arm)) in patients with RA in stable remission. METHODS: In 2015, clinical data for the completer population were retrospectively collected at 1, 2 and 3 years after the end of the trial. The endpoints were the proportion of patients free of a biological disease-modifying antirheumatic drug (bDMARD) treatment, a sustainably spaced injection of TNF-blockers and a full-dose regimen as well as the mean dose of bDMARD intake and treatment switch rate. RESULTS: Overall, 96 patients (76.8% of the completers) had data available up to 3 years; 11.5% discontinued TNF-blockers (5.8% vs 18.2% in the M-arm and S-arm, p=0.06), 30.2% had a tapered regimen (28.8% vs 31.8%, p=0.76) and 37.5% retained a full dose (44.2% vs 29.5%, p=0.14). The mean TNF-blocker dose quotient was 66% of the full dose (74% vs 58% in the M-arm and S-arm, p=0.06); 20.8% switched to another bDMARD (21.2% vs 20.5%, p=0.94). CONCLUSION: Sustained TNF-blocker de-escalation or withdrawal is achievable in 41% of patients over 3 years with limited dose reduction. Optimal strategies remain to be determined to maintain remission after TNF-blocker tapering or discontinuation.
引用
- Sigaux J, Bailly F, Hajage D, et al. Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial. RMD Open. 2017. PMID: 28955495. doi:10.1136/rmdopen-2017-000474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。